Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
In this article
Merck
will acquire Cidara Therapeutics
in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
Merck is looking to diversify its revenue beyond Keytruda as its patents for the blockbuster drug start to expire later this decade.
San Diego company’s lead drug is a potential alternative to vaccines for vulnerable patients
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster…
The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of its…
Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for…
The program will sell Xofluza through three pharmacies with a $50 cash pay option, which is 70% lower than the pill's current…
Pfizer shows hardball mettle needed to win in 2025 M&A
